Exciton Pharma Corp, Toronto, ON M5G 1L7, Canada.
Exciton Pharma Corp, Toronto, ON M5G 1L7, Canada.
Int J Pharm. 2020 Apr 30;580:119197. doi: 10.1016/j.ijpharm.2020.119197. Epub 2020 Mar 4.
Topical semi-solid formulations are ubiquitous in personal care and pharmaceutical applications. For centuries, these topical formulations have facilitated delivery of active ingredients such as botanical oils, medicinal extracts and more recently antibiotics and biologics. Numerous strategies exist for the stabilization and release of these active ingredients from semi-solid formulations, namely, inclusion of anti-oxidants and surfactants to extend shelf life and facilitate delivery respectively. However, in the instance where the active ingredient itself is an oxidizing agent, traditional strategies for formulation have limited utility. Recent evidence has highlighted the exceptional efficacy and safety of highly oxidizing silver compounds, containing Ag and Ag. These higher oxidation states of silver provide antimicrobial and antibiofilm activity without impairing healing. However, as strong oxidizing agents, their application in medical device and pharmaceutical formulations such as semi-solid formulations are limited. The present study reports on the development of a silicone-based gel formulation of silver oxynitrate (AgNO), a higher oxidation state silver complex. In this study the chemical stability of silver oxynitrate was examined through solid state characterization with X-ray diffraction, formulation stability and microstructure of the semi-solid gel evaluated through various rheological techniques, therapeutic functionality of the semi-solid formulation investigated through in-vitro planktonic and biofilm antimicrobial studies, and biocompatibility assessed though in-vitro mammalian fibroblast and in-vivo porcine wound healing models. Enhanced stability of silver oxynitrate within the semi-solid formulation was observed over a four-month X-ray diffraction study. At the end of the study, silver oxynitrate was identified as the principal diffraction pattern in the semi-solid formulation where argentic oxide diffraction peaks were observed to be dominant in silver oxynitrate powders alone. Viscoelastic or gel-like behavior of the formulation was observed under dynamic rheological study where the storage modulus (G' = 1.77 ± 0.02 × 10 Pa) significantly exceeded the loss modulus (G″ = 4.89 ± 3.72 × 10 Pa) (p < 0.0001). No significant (p = 0.84) change was observed in the apparent viscous response within the last three months of the study period indicative that the formulation approached a steady rheological state. The silver oxynitrate semi-solid formulation provided sustained in-vitro antimicrobial activity (>99.99% kill) over seven days with a significant reduction in biofilm within 6 h (p < 0.001). In-vitro mammalian fibroblast studies demonstrated the formulation to be non-cytotoxic and 100% epithelialization was observed within a six-day in-vivo porcine deep partial-thickness wound. The improved chemical stability, biocompatibility and efficacy results indicate that silicone gel semi-solid formulation may be a promising medicinal configuration to facilitate expansion of the clinical use of silver oxynitrate.
局部半固体制剂在个人护理和制药应用中无处不在。几个世纪以来,这些局部制剂促进了活性成分的递送,如植物精油、药用提取物,以及最近的抗生素和生物制剂。为了从半固体制剂中稳定和释放这些活性成分,存在许多策略,例如添加抗氧化剂和表面活性剂来分别延长保质期和促进递送。然而,在活性成分本身是氧化剂的情况下,传统的制剂策略的实用性有限。最近的证据强调了高度氧化的银化合物(含有 Ag 和 Ag )的出色功效和安全性。这些更高的氧化态银提供了抗菌和抗生物膜活性,而不会损害愈合。然而,作为强氧化剂,它们在医疗器械和半固体制剂等药物制剂中的应用受到限制。本研究报告了开发一种基于硅酮的硝酸氧银(AgNO)凝胶制剂的情况,AgNO 是一种更高氧化态的银配合物。在这项研究中,通过 X 射线衍射进行了固态特征研究,考察了硝酸氧银的化学稳定性,通过各种流变技术评估了半固体制剂的稳定性和微观结构,通过体外浮游和生物膜抗菌研究研究了半固体制剂的治疗功能,并通过体外哺乳动物成纤维细胞和体内猪伤口愈合模型评估了生物相容性。在为期四个月的 X 射线衍射研究中,观察到半固体制剂中硝酸氧银的稳定性增强。在研究结束时,发现硝酸氧银是半固体制剂中的主要衍射图案,而在单独的硝酸氧银粉末中观察到银氧化物衍射峰占主导地位。在动态流变研究中观察到制剂的粘弹性或凝胶状行为,其中储能模量(G'=1.77±0.02×10 Pa)明显超过损耗模量(G″=4.89±3.72×10 Pa)(p<0.0001)。在研究期间的最后三个月内,观察到表观粘性响应没有明显变化(p=0.84),表明制剂接近稳定的流变状态。硝酸氧银半固体制剂在 7 天内提供持续的体外抗菌活性(>99.99%杀菌),并在 6 小时内显著减少生物膜(p<0.001)。体外哺乳动物成纤维细胞研究表明该制剂无细胞毒性,并且在体内猪深部分层伤口的六天内观察到 100%上皮化。改善的化学稳定性、生物相容性和功效结果表明,硅酮凝胶半固体制剂可能是一种有前途的药用配方,可以促进硝酸氧银的临床应用扩展。